Testing effectiveness (Phase 2)Not Yet RecruitingNCT06258018What this trial is testingNiraparib and Temozolomide in Patients GlioblastomaWho this might be right forGlioma, Malignant Armando Santoro, MD 86
Very early researchUnknownNCT02766270What this trial is testingCCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III GliomasWho this might be right forGrade II/III Glioma Beijing Tiantan Hospital 30
Testing effectiveness (Phase 2)UnknownNCT04614493What this trial is testingInnovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.Who this might be right forInitial Radiological Diagnosis Eligible for Tumor ResectionInitial Radiological Diagnosis Compatible With Newly Diagnosed Glioblastoma (IDH Wild-type)Eligible for the Standard of Care Including Concurrent Temoradiation and Adjuvant Temozolomide Assistance Publique - Hôpitaux de Paris 66
Early research (Phase 1)Study completedNCT06095375What this trial is testingRegorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM PatientsWho this might be right forGlioblastoma, IDH-wildtypeMGMT-Methylated Glioblastoma Istituto Oncologico Veneto IRCCS 21
Testing effectiveness (Phase 2)Ended earlyNCT03897491What this trial is testingPD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type GlioblastomaWho this might be right forGlioblastoma photonamic GmbH & Co. KG 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT05859334What this trial is testingTesting the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following TreatmentWho this might be right forRecurrent GliomaRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more National Cancer Institute (NCI) 30
Testing effectiveness (Phase 2)Looking for participantsNCT07185880What this trial is testingThe Safety and Tolerability of MT-125 in GBM PatientsWho this might be right forGlioblastoma (GBM) Myosin Therapeutics Inc. 36
Not applicableNot Yet RecruitingNCT06368934What this trial is testingSub-lobectomy for IDH Wild-type and TERT Promoter Mutant GlioblastomaWho this might be right forGliomaGlioblastoma Huashan Hospital 326
Not applicableNot Yet RecruitingNCT07788430What this trial is testingImpact of Pesticide Exposure on Survival and Tumor Aggressiveness in Patients With Glioblastoma: A Prospective Clinical StudyWho this might be right forGlioblastoma IDH (Isocitrate Dehydrogenase) Wildtype Institut Claudius Regaud 120
Early research (Phase 1)Looking for participantsNCT07223034What this trial is testing177Lu-PSMA-617 in People With GliomasWho this might be right forGliomaDiffuse Astrocytoma, IDH-Wildtype (Grade 2-4)Glioblastoma, IDH-wildtype+3 more Memorial Sloan Kettering Cancer Center 20
Testing effectiveness (Phase 2)Looking for participantsNCT05871021What this trial is testingProtective VEGF Inhibition for Isotoxic Dose Escalation in GlioblastomaWho this might be right forGlioblastoma University Hospital Tuebingen 146
Large-scale testing (Phase 3)Looking for participantsNCT03970447What this trial is testingA Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaWho this might be right forGlioblastoma Global Coalition for Adaptive Research 2,250
Testing effectiveness (Phase 2)Study completedNCT03234595What this trial is testingA Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade GliomaWho this might be right forRecurrent GBM Everfront Biotech Co., Ltd. 22
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07604285What this trial is testingSafety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated GlioblastomaWho this might be right forGlioblastoma Myosin Therapeutics Inc. 36
Testing effectiveness (Phase 2)Ended earlyNCT05267106What this trial is testingStudy to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 AlterationsWho this might be right forGlioblastomaAdult-type Diffuse Gliomas Incyte Corporation 83
Testing effectiveness (Phase 2)Looking for participantsNCT03649880What this trial is testingFeasibility of FMISO in Brain TumorsWho this might be right forIDH Wild Type Glioblastoma OHSU Knight Cancer Institute 77
Testing effectiveness (Phase 2)Looking for participantsNCT05664464What this trial is testingGlutamate Inhibitors in GlioblastomaWho this might be right forGlioblastoma University of Zurich 120
Not applicableLooking for participantsNCT06964815What this trial is testingSilibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma PatientsWho this might be right forGlioblastomaIDH Wild-type and STAT3-positive Glioblastoma Istituto Oncologico Veneto IRCCS 110
Testing effectiveness (Phase 2)WithdrawnNCT05218408What this trial is testingCYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild TypeWho this might be right forAstrocytoma, Grade IVGlioblastomaGiant Cell Glioblastoma+1 more Celularity Incorporated
Very early researchLooking for participantsNCT06552260What this trial is testingA Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type GlioblastomaWho this might be right forGlioblastomaRecurrent GlioblastomaBrain Tumor Ugonma Chukwueke 27